Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$155.68
-2.1%
$163.46
$82.09
$189.97
$4.44B0.85366,250 shs242,413 shs
Veradigm Inc. stock logo
MDRX
Veradigm
$7.95
-1.0%
$7.76
$5.01
$14.09
$868.62M0.653.81 million shs61,088 shs
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
$23.94
$23.89
$15.23
$23.98
$1.61B0.77659,586 shsN/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
$52.28
-0.4%
$49.24
$24.83
$54.79
$2.69B1.01499,007 shs498,157 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-1.85%-6.24%-6.14%+31.78%+82.00%
Veradigm Inc. stock logo
MDRX
Veradigm
+1.01%+6.36%+7.07%-14.39%-36.72%
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
0.00%0.00%0.00%0.00%+37.03%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-2.36%+1.33%+11.64%+13.89%+46.96%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.0999 of 5 stars
2.51.00.04.72.73.31.9
Veradigm Inc. stock logo
MDRX
Veradigm
2.2532 of 5 stars
3.10.00.04.12.50.01.3
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
N/AN/AN/AN/AN/AN/AN/AN/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
0.3421 of 5 stars
1.50.00.00.01.83.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$171.009.84% Upside
Veradigm Inc. stock logo
MDRX
Veradigm
2.20
Hold$11.2541.51% Upside
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
2.00
Hold$21.98-8.17% Downside
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
3.00
Buy$45.60-12.78% Downside

Current Analyst Ratings

Latest MDRX, NXGN, PRCT, and KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00
4/16/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$178.00 ➝ $204.00
3/19/2024
Veradigm Inc. stock logo
MDRX
Veradigm
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $10.00
2/28/2024
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$55.00 ➝ $58.00
2/27/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $175.00
2/27/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$160.00 ➝ $195.00
2/27/2024
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$50.70M87.54N/AN/A$27.60 per share5.64
Veradigm Inc. stock logo
MDRX
Veradigm
$1.50B0.58$2.75 per share2.89N/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
$653.17M2.46$1.16 per share20.57$6.31 per share3.79
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
$136.19M19.73N/AN/A$5.56 per share9.40

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$10.93M$0.081,946.2439.31N/AN/A-13.31%-12.61%5/13/2024 (Estimated)
Veradigm Inc. stock logo
MDRX
Veradigm
$134.44MN/A0.0010.19N/AN/AN/AN/AN/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
-$2.65M-$0.10N/A27.52N/A-0.89%11.37%5.38%N/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$105.90M-$2.24N/AN/AN/A-77.75%-46.59%-30.63%5/1/2024 (Confirmed)

Latest MDRX, NXGN, PRCT, and KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$0.55N/A+$0.55N/AN/AN/A  
2/27/2024Q4 2023
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
-$0.44-$0.54-$0.10-$0.54$41.79 million$43.58 million      
2/26/202412/31/2023
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Veradigm Inc. stock logo
MDRX
Veradigm
N/AN/AN/AN/AN/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
17.76
17.55
Veradigm Inc. stock logo
MDRX
Veradigm
N/AN/AN/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
0.63
2.52
2.52
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
0.18
7.63
6.77

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Veradigm Inc. stock logo
MDRX
Veradigm
N/A
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
76.65%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
89.46%

Insider Ownership

CompanyInsider Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
14.10%
Veradigm Inc. stock logo
MDRX
Veradigm
2.29%
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
4.60%
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
19.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
22928.51 million24.49 millionOptionable
Veradigm Inc. stock logo
MDRX
Veradigm
8,000109.26 million106.76 millionOptionable
NextGen Healthcare, Inc. stock logo
NXGN
NextGen Healthcare
2,78367.10 million64.01 millionOptionable
PROCEPT BioRobotics Co. stock logo
PRCT
PROCEPT BioRobotics
62651.40 million40.98 millionOptionable

MDRX, NXGN, PRCT, and KRYS Headlines

SourceHeadline
PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week High at $54.79PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week High at $54.79
marketbeat.com - April 24 at 1:55 PM
PRCT PROCEPT BioRobotics CorporationPRCT PROCEPT BioRobotics Corporation
seekingalpha.com - April 24 at 3:32 AM
PROCEPT BioRobotics (PRCT) Set to Announce Earnings on WednesdayPROCEPT BioRobotics (PRCT) Set to Announce Earnings on Wednesday
americanbankingnews.com - April 24 at 2:20 AM
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual MeetingPROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
globenewswire.com - April 23 at 8:00 AM
PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stake Lowered by Allspring Global Investments Holdings LLCPROCEPT BioRobotics Co. (NASDAQ:PRCT) Stake Lowered by Allspring Global Investments Holdings LLC
marketbeat.com - April 18 at 5:22 AM
Contrasting SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)Contrasting SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)
americanbankingnews.com - April 16 at 3:20 AM
PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 3.5%PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 3.5%
marketbeat.com - April 15 at 5:31 PM
PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 12-Month High at $53.54PROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 12-Month High at $53.54
marketbeat.com - April 11 at 10:45 AM
Experts Top 5 AI Stocks With Huge PotentialExperts Top 5 AI Stocks With Huge Potential
msn.com - April 8 at 7:34 PM
PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 4.4%PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 4.4%
marketbeat.com - April 5 at 2:18 PM
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, TexasPROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
globenewswire.com - April 4 at 4:04 PM
Ballentine Partners LLC Purchases Shares of 133,000 PROCEPT BioRobotics Co. (NASDAQ:PRCT)Ballentine Partners LLC Purchases Shares of 133,000 PROCEPT BioRobotics Co. (NASDAQ:PRCT)
marketbeat.com - April 3 at 5:38 PM
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
globenewswire.com - April 2 at 4:03 PM
PROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Consensus Rating of "Buy" from AnalystsPROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Consensus Rating of "Buy" from Analysts
marketbeat.com - April 2 at 4:22 AM
Brokers Issue Forecasts for PROCEPT BioRobotics Co.s Q2 2025 Earnings (NASDAQ:PRCT)Brokers Issue Forecasts for PROCEPT BioRobotics Co.'s Q2 2025 Earnings (NASDAQ:PRCT)
marketbeat.com - March 31 at 1:48 AM
Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 441 Shares of StockInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 441 Shares of Stock
insidertrades.com - March 21 at 10:33 AM
Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells 1,024 Shares of StockInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells 1,024 Shares of Stock
insidertrades.com - March 21 at 10:32 AM
PROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company SharesPROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company Shares
finance.yahoo.com - March 20 at 7:23 PM
PRCT Oct 2024 55.000 callPRCT Oct 2024 55.000 call
finance.yahoo.com - March 18 at 10:46 AM
Alaleh Nouri Sells 2,749 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockAlaleh Nouri Sells 2,749 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stock
insidertrades.com - March 17 at 8:17 AM
PRCT Apr 2024 50.000 putPRCT Apr 2024 50.000 put
ca.finance.yahoo.com - March 16 at 9:52 AM
EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)
finance.yahoo.com - March 8 at 9:35 AM
Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)
finance.yahoo.com - March 7 at 12:14 AM
Noteworthy Wednesday Option Activity: ZM, PRCT, MSTRNoteworthy Wednesday Option Activity: ZM, PRCT, MSTR
nasdaq.com - March 1 at 2:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Krystal Biotech logo

Krystal Biotech

NASDAQ:KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Veradigm logo

Veradigm

NASDAQ:MDRX
Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
NextGen Healthcare logo

NextGen Healthcare

NASDAQ:NXGN
NextGen Healthcare, Inc. provides healthcare technology solutions in the United States. The company offers clinical care solutions, including NextGen Enterprise EHR; financial solutions, such as NextGen Enterprise PM; patient engagement solutions comprising NextGen Virtual Visits; integrated clinical care and financial solutions consisting of NextGen Office; interoperability solutions that include NextGen Share and Mirth Connect; data and analytics solutions, which comprise NextGen Health Data Hub; and value based care solutions, including NextGen Population Health Solutions. It also provides managed services, such as revenue cycle management services comprising billing and collections, electronic claims submission and denials management, electronic remittance and payment posting, and accounts receivable follow-up; and client and support services. Further, the company offers professional services consisting of training, project management, installation services, and application managed services; and consulting services that include physician, professional, and technical consulting; assisting clients to optimize their staffing and software solutions; enhancing financial and clinical outcomes; achieving regulatory requirements; and meeting the requirements of healthcare reform. It serves accountable care organizations, independent physician associations, managed service organizations, veterans service organizations, dental service organizations, ambulatory care centers, and community health centers through a direct sales force and reseller channel. The company was formerly known as Quality Systems, Inc. and changed its name to NextGen Healthcare, Inc. in September 2018. NextGen Healthcare, Inc. was incorporated in 1974 and is based in Atlanta, Georgia.
PROCEPT BioRobotics logo

PROCEPT BioRobotics

NASDAQ:PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.